During the corresponding time, Intercure Ltd recorded a revenue increase by 318.38 % year on year, While revenue at the Intercure Ltd 's corporate clients
Intercure Ltd's Comment on Sales, Marketing and Customers
The company serves licensed pharmacies, including Super Pharm, through licensed distributors such as Novolog, SLE, N.D.N., and its own trade houses. It holds an exclusive license agreement with Cookies to use the Cookies brand in Israel, operating Cookies-branded pharmacies in Jerusalem and Be’er Sheva. The company plans to expand Cookies-branded products into Europe via joint ventures focused on cultivation, manufacturing, and distribution. It has a multi-year agreement with Cookies to establish Cookies stores and medical cannabis pharmacies in Austria and the UK; however, operations in Austria have ceased and UK plans are currently on hold. In August 2024, the company entered a new strategic agreement with Cookies to cultivate, manufacture, import, and distribute Cookies-branded products in eight licensed pharmacies in Germany, marking an expansion in Europe that includes the UK, Austria, and Germany. The company will cultivate and manufacture Cookies licensed genetics and products at its global supply chain facilities and develop next-generation products. Additionally, it maintains a strategic collaboration with Tilray, a global cannabis company operating in 16 countries, established in December 2019 to access markets within Tilray’s territories.
Intercure Ltd’s Comment on Sales, Marketing and Customers
The company serves licensed pharmacies, including Super Pharm, through licensed distributors such as Novolog, SLE, N.D.N., and its own trade houses. It holds an exclusive license agreement with Cookies to use the Cookies brand in Israel, operating Cookies-branded pharmacies in Jerusalem and Be’er Sheva. The company plans to expand Cookies-branded products into Europe via joint ventures focused on cultivation, manufacturing, and distribution. It has a multi-year agreement with Cookies to establish Cookies stores and medical cannabis pharmacies in Austria and the UK; however, operations in Austria have ceased and UK plans are currently on hold. In August 2024, the company entered a new strategic agreement with Cookies to cultivate, manufacture, import, and distribute Cookies-branded products in eight licensed pharmacies in Germany, marking an expansion in Europe that includes the UK, Austria, and Germany. The company will cultivate and manufacture Cookies licensed genetics and products at its global supply chain facilities and develop next-generation products. Additionally, it maintains a strategic collaboration with Tilray, a global cannabis company operating in 16 countries, established in December 2019 to access markets within Tilray’s territories.
Sources:
Intercure Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Intercure Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Intercure Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %